Portfolio Holdings Detail for ISIN GB0001990497
| Stock Name / Fund | City Of London Investment Trust |
| Issuer | |
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 63
| Common Stock Ticker | CTY(GBX) LSE |
| Common Stock Ticker | CLN(EUR) F |
| Common Stock Ticker | CTY.LS(GBX) CXE |
| Common Stock Ticker | CTY.L(GBP) LSE |
Holdings detail for GSK
| Stock Name | GlaxoSmithKline PLC |
| Ticker | GSK(GBX) LSE |
| TYPE | Common Stock |
| Country | UK |
| ISIN | GB00BN7SWP63 |
| LEI | 5493000HZTVUYLO1D793 |
Show aggregate GSK holdings
News associated with GSK
- GSK (LON:GSK) Stock Passes Above Two Hundred Day Moving Average – What’s Next?
- GSK plc (LON:GSK – Get Free Report)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,444 ($18.73) and traded as high as GBX 1,523.50 ($19.76). GSK shares last traded at GBX 1,490 ($19.32), with a volume of 10,344,893 shares trading hands. […] - 2025-03-13 07:00:45
- Atria Investments Inc Cuts Stake in GSK plc (NYSE:GSK)
- Atria Investments Inc cut its holdings in GSK plc (NYSE:GSK – Free Report) by 7.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 37,066 shares of the pharmaceutical company’s stock after selling 3,042 shares during the quarter. Atria Investments Inc’s […] - 2025-03-12 09:05:15
- M&T Bank Corp Reduces Holdings in GSK plc (NYSE:GSK)
- M&T Bank Corp cut its position in GSK plc (NYSE:GSK – Free Report) by 10.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,789 shares of the pharmaceutical company’s stock after selling 5,750 shares during the quarter. M&T Bank Corp’s holdings in GSK were […] - 2025-03-11 10:48:50
- GSK: Depemokimab Shows Significant Improvements For CRSwNP Patients In Phase III Trials
- (RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps or CRSwNP in phase III trials. - 2025-03-03 07:45:28
- Ieq Capital LLC Boosts Position in GSK plc (NYSE:GSK)
- Ieq Capital LLC grew its position in shares of GSK plc (NYSE:GSK – Free Report) by 10.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,567 shares of the pharmaceutical company’s stock after purchasing an additional 910 shares during the period. […] - 2025-02-28 09:23:04
- Wednesday's ETF with Unusual Volume: GMOI
- The GMO International Value ETF is seeing unusually high volume in afternoon trading Wednesday, with over 512,000 shares traded versus three month average volume of about 44,000. Shares of GMOI were trading flat on the day.
Components of that ETF with the highest volume on Wed - 2025-02-26 17:43:10
- GSK plc (NYSE:GSK) Shares Sold by Atria Wealth Solutions Inc.
- Atria Wealth Solutions Inc. lowered its position in GSK plc (NYSE:GSK – Free Report) by 19.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,765 shares of the pharmaceutical company’s stock after selling 5,040 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in […] - 2025-02-26 08:47:02
- Valeo Financial Advisors LLC Sells 3,907 Shares of GSK plc (NYSE:GSK)
- Valeo Financial Advisors LLC lowered its position in GSK plc (NYSE:GSK – Free Report) by 31.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,380 shares of the pharmaceutical company’s stock after selling 3,907 shares during the period. […] - 2025-02-18 09:14:50
- Kestra Private Wealth Services LLC Sells 4,071 Shares of GSK plc (NYSE:GSK)
- Kestra Private Wealth Services LLC decreased its stake in shares of GSK plc (NYSE:GSK – Free Report) by 23.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 13,130 shares of the pharmaceutical company’s stock after selling 4,071 shares during the quarter. Kestra […] - 2025-02-17 08:22:52
- FDA Approves GSK's Penmenvy, 5-in-1 Meningococcal Vaccine For MenABCWY Protection
- (RTTNews) - GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 years. The vaccine targets five major serogroups of Neisseria meningitidis (A, B, C - 2025-02-17 07:12:23
- GSK plc (NYSE:GSK) Shares Sold by Kingsview Wealth Management LLC
- Kingsview Wealth Management LLC lowered its holdings in GSK plc (NYSE:GSK – Free Report) by 11.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,956 shares of the pharmaceutical company’s stock after selling 2,024 shares during the period. Kingsview Wealth Management LLC’s […] - 2025-02-14 09:46:55
- Apollon Wealth Management LLC Increases Stock Holdings in GSK plc (NYSE:GSK)
- Apollon Wealth Management LLC raised its stake in shares of GSK plc (NYSE:GSK – Free Report) by 9.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,279 shares of the pharmaceutical company’s stock after purchasing an additional 1,634 shares during […] - 2025-02-13 10:31:16
- GSK plc (NYSE:GSK) Shares Sold by Stratos Wealth Partners LTD.
- Stratos Wealth Partners LTD. trimmed its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 11.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,007 shares of the pharmaceutical company’s stock after selling 2,111 shares during the quarter. Stratos Wealth […] - 2025-02-12 08:36:56
- Fund Update: PRIMECAP MANAGEMENT CO/CA/ Just Disclosed New Holdings
- PRIMECAP MANAGEMENT CO/CA/ just filed a portfolio update, which we received from a 13F disclosure. This disclosure reflects the funds' holdings for the 12-31-2024 report period. You can see the full portfolio on Quiver Quantitative, and track moves made by other funds. - 2025-02-10 21:13:19
- DAVENPORT & Co LLC Sells 723 Shares of GSK plc (NYSE:GSK)
- DAVENPORT & Co LLC lessened its position in shares of GSK plc (NYSE:GSK – Free Report) by 4.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,324 shares of the pharmaceutical company’s stock after selling 723 shares during the period. DAVENPORT & Co LLC’s […] - 2025-02-08 08:50:51
- Kratos Defense and GSK have been highlighted as Zacks Bull and Bear of the Day
- Kratos Defense and GSK have been highlighted as Zacks Bull and Bear of the Day. - 2025-02-06 10:00:00
- Greenleaf Trust Has $251,000 Stock Holdings in GSK plc (NYSE:GSK)
- Greenleaf Trust trimmed its position in shares of GSK plc (NYSE:GSK – Free Report) by 10.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,410 shares of the pharmaceutical company’s stock after selling 859 shares during the period. […] - 2025-02-06 08:50:53
- GSK (NYSE:GSK) Shares Gap Up on Earnings Beat
- GSK plc (NYSE:GSK – Get Free Report) gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $34.84, but opened at $37.06. GSK shares last traded at $37.57, with a volume of 920,933 shares. The pharmaceutical company reported $0.59 earnings per share (EPS) for the […] - 2025-02-06 06:54:50
- Caprock Group LLC Purchases 1,424 Shares of GSK plc (NYSE:GSK)
- Caprock Group LLC lifted its holdings in GSK plc (NYSE:GSK – Free Report) by 7.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 19,942 shares of the pharmaceutical company’s stock after buying an additional 1,424 shares during the period. Caprock Group LLC’s holdings in GSK were worth $684,000 at the end of the most […] - 2025-02-04 08:59:07
- Brokerages Set GSK plc (NYSE:GSK) Price Target at $43.25
- Shares of GSK plc (NYSE:GSK – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and three have given a strong buy recommendation to the company. The average 1-year […] - 2025-02-04 06:47:00
- Geneos Wealth Management Inc. Makes New Investment in GSK plc (NYSE:GSK)
- Geneos Wealth Management Inc. purchased a new stake in shares of GSK plc (NYSE:GSK – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 4,292 shares of the pharmaceutical company’s stock, valued at approximately $145,000. Several other institutional investors […] - 2025-01-31 08:48:56
City Of London Investment Trust GSK holdings
| Date | Number of GSK Shares Held | Base Market Value of GSK Shares | Local Market Value of GSK Shares | Change in GSK Shares Held | Change in GSK Base Value | Current Price per GSK Share Held | Previous Price per GSK Share Held |
|---|
| 2024-03-01 (Friday) |
Deprecated: number_format(): Passing null to parameter #1 ($num) of type float is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 117
0 | 42,728,000 |
Deprecated: number_format(): Passing null to parameter #1 ($num) of type float is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 125
0 | | | | |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projectionThe likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of GSK
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-03-12 | 902,654 | 762 | 1,922,792 | 46.9% |
| 2025-03-11 | 1,439,447 | 15,326 | 2,222,302 | 64.8% |
| 2025-03-10 | 1,465,821 | 6,115 | 2,706,871 | 54.2% |
| 2025-03-07 | 1,398,055 | 8,063 | 2,233,625 | 62.6% |
| 2025-03-06 | 1,123,196 | 1,246 | 2,612,891 | 43.0% |
| 2025-03-05 | 639,462 | 35 | 961,318 | 66.5% |
| 2025-03-04 | 1,317,719 | 3,647 | 2,226,653 | 59.2% |
| 2025-03-03 | 838,181 | 6,086 | 1,402,384 | 59.8% |
| 2025-02-28 | 1,287,904 | 1,158 | 3,316,216 | 38.8% |
| 2025-02-27 | 2,686,029 | 4,472 | 5,113,540 | 52.5% |
| 2025-02-26 | 3,074,282 | 1,231 | 3,887,906 | 79.1% |
| 2025-02-25 | 2,386,180 | 5,481 | 5,522,896 | 43.2% |
| 2025-02-24 | 668,749 | 4,847 | 1,203,834 | 55.6% |
| 2025-02-21 | 1,255,579 | 7,553 | 2,278,021 | 55.1% |
| 2025-02-20 | 1,683,476 | 49,026 | 2,781,469 | 60.5% |
| 2025-02-19 | 620,362 | 13,952 | 1,524,168 | 40.7% |
| 2025-02-18 | 876,547 | 1,317 | 1,947,179 | 45.0% |
| 2025-02-14 | 1,230,199 | 653 | 2,066,692 | 59.5% |
| 2025-02-13 | 774,632 | 57 | 1,729,972 | 44.8% |
| 2025-02-12 | 566,251 | 2,662 | 1,346,241 | 42.1% |
| 2025-02-11 | 901,543 | 287 | 2,447,688 | 36.8% |
| 2025-02-10 | 968,610 | 2,984 | 1,821,894 | 53.2% |
| 2025-02-07 | 1,176,427 | 965 | 2,187,503 | 53.8% |
| 2025-02-06 | 2,050,331 | 2,132 | 2,902,832 | 70.6% |
| 2025-02-05 | 1,859,969 | 7,158 | 4,188,377 | 44.4% |
| 2025-02-04 | 1,105,587 | 3,749 | 2,968,034 | 37.2% |
| 2025-02-03 | 668,584 | 2,272 | 1,208,270 | 55.3% |
| 2025-01-31 | 1,133,136 | 671 | 1,724,883 | 65.7% |
| 2025-01-30 | 1,163,997 | 4,443 | 2,070,574 | 56.2% |
| 2025-01-29 | 1,263,657 | 0 | 2,102,457 | 60.1% |
| 2025-01-28 | 856,898 | 260 | 1,549,549 | 55.3% |
| 2025-01-27 | 1,269,311 | 2,631 | 2,100,641 | 60.4% |
| 2025-01-24 | 888,732 | 453 | 1,476,003 | 60.2% |
| 2025-01-23 | 869,089 | 3,781 | 1,297,691 | 67.0% |
| 2025-01-22 | 979,352 | 9,629 | 1,677,917 | 58.4% |
| 2025-01-21 | 1,143,580 | 890 | 2,032,145 | 56.3% |
| 2025-01-17 | 897,953 | 344 | 1,496,734 | 60.0% |
| 2025-01-16 | 683,568 | 917 | 1,717,051 | 39.8% |
| 2025-01-15 | 807,034 | 2,823 | 1,782,138 | 45.3% |
| 2025-01-14 | 1,239,396 | 3,610 | 2,448,176 | 50.6% |
| 2025-01-13 | 803,595 | 50 | 2,202,181 | 36.5% |
| 2025-01-10 | 720,410 | 2,543 | 1,508,173 | 47.8% |
| 2025-01-08 | 713,651 | 646 | 1,115,043 | 64.0% |
| 2025-01-07 | 795,999 | 289 | 1,321,010 | 60.3% |
| 2025-01-06 | 808,114 | 2,203 | 1,262,368 | 64.0% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.